| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy | 14 | 2021 | 95 | 4.810 |
Why?
|
| Killer Cells, Natural | 11 | 2019 | 92 | 3.660 |
Why?
|
| CD8-Positive T-Lymphocytes | 10 | 2021 | 159 | 2.990 |
Why?
|
| Neoplasms | 16 | 2020 | 1103 | 2.680 |
Why?
|
| Antineoplastic Agents | 13 | 2021 | 803 | 2.680 |
Why?
|
| Lung Neoplasms | 10 | 2023 | 358 | 2.630 |
Why?
|
| Lymphocytes | 4 | 2023 | 118 | 2.530 |
Why?
|
| Cell Communication | 9 | 2023 | 97 | 2.230 |
Why?
|
| T-Lymphocytes | 12 | 2019 | 357 | 2.180 |
Why?
|
| Immunotherapy, Adoptive | 5 | 2020 | 16 | 1.790 |
Why?
|
| Kidney Neoplasms | 8 | 2021 | 68 | 1.760 |
Why?
|
| Immunity, Innate | 7 | 2019 | 149 | 1.630 |
Why?
|
| Cytotoxicity, Immunologic | 8 | 2019 | 24 | 1.510 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 5 | 2020 | 20 | 1.470 |
Why?
|
| Antibodies, Monoclonal | 3 | 2019 | 290 | 1.330 |
Why?
|
| Immunomodulation | 4 | 2019 | 15 | 1.310 |
Why?
|
| Adaptive Immunity | 5 | 2019 | 27 | 1.300 |
Why?
|
| Antigens, Neoplasm | 5 | 2015 | 59 | 1.240 |
Why?
|
| Cytokines | 6 | 2021 | 602 | 1.230 |
Why?
|
| Animals | 45 | 2024 | 15081 | 1.190 |
Why?
|
| Thymus Gland | 7 | 2004 | 81 | 1.080 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2022 | 194 | 1.060 |
Why?
|
| Mitochondria | 4 | 2024 | 487 | 1.030 |
Why?
|
| Lymphoma, T-Cell | 6 | 2003 | 28 | 1.000 |
Why?
|
| Mice | 27 | 2024 | 5913 | 0.920 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2019 | 20 | 0.910 |
Why?
|
| Mice, Inbred BALB C | 15 | 2021 | 661 | 0.840 |
Why?
|
| Signal Transduction | 16 | 2021 | 1908 | 0.780 |
Why?
|
| Receptors, Notch | 4 | 2020 | 33 | 0.780 |
Why?
|
| Proteasome Endopeptidase Complex | 3 | 2017 | 114 | 0.770 |
Why?
|
| Adenocarcinoma | 2 | 2017 | 251 | 0.760 |
Why?
|
| Neuroimmunomodulation | 1 | 2020 | 13 | 0.750 |
Why?
|
| Tumor Escape | 7 | 2020 | 13 | 0.740 |
Why?
|
| Neurotransmitter Agents | 1 | 2020 | 63 | 0.720 |
Why?
|
| Dendritic Cells | 2 | 2019 | 113 | 0.710 |
Why?
|
| Fas Ligand Protein | 4 | 2015 | 16 | 0.690 |
Why?
|
| Humans | 38 | 2023 | 37093 | 0.650 |
Why?
|
| NF-kappa B | 3 | 2017 | 339 | 0.640 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 182 | 0.620 |
Why?
|
| Natural Killer T-Cells | 1 | 2017 | 9 | 0.600 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2017 | 5 | 0.590 |
Why?
|
| Fibrosarcoma | 1 | 2017 | 8 | 0.590 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2021 | 807 | 0.590 |
Why?
|
| Combined Modality Therapy | 5 | 2019 | 148 | 0.580 |
Why?
|
| Cancer Vaccines | 2 | 2020 | 21 | 0.570 |
Why?
|
| Multiple Myeloma | 1 | 2017 | 39 | 0.570 |
Why?
|
| Breast Neoplasms | 3 | 2017 | 1502 | 0.560 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2015 | 88 | 0.560 |
Why?
|
| Boronic Acids | 4 | 2010 | 19 | 0.560 |
Why?
|
| Pyrazines | 4 | 2010 | 24 | 0.560 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2015 | 6 | 0.540 |
Why?
|
| Cell Line, Tumor | 12 | 2023 | 2231 | 0.530 |
Why?
|
| Immune System Diseases | 1 | 2015 | 21 | 0.530 |
Why?
|
| MicroRNAs | 1 | 2021 | 426 | 0.520 |
Why?
|
| Membrane Proteins | 6 | 2024 | 517 | 0.460 |
Why?
|
| Mice, Transgenic | 5 | 2017 | 617 | 0.440 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 3 | 2010 | 10 | 0.430 |
Why?
|
| Aging | 3 | 2022 | 664 | 0.410 |
Why?
|
| Homeodomain Proteins | 2 | 2015 | 132 | 0.410 |
Why?
|
| Receptor Cross-Talk | 1 | 2011 | 17 | 0.410 |
Why?
|
| Virus Diseases | 1 | 2011 | 22 | 0.400 |
Why?
|
| Neoplasm Transplantation | 7 | 2010 | 122 | 0.400 |
Why?
|
| Apoptosis | 8 | 2021 | 1398 | 0.400 |
Why?
|
| Inflammation | 4 | 2024 | 618 | 0.390 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 2 | 2010 | 2 | 0.380 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2023 | 88 | 0.380 |
Why?
|
| Cell Count | 2 | 2013 | 135 | 0.370 |
Why?
|
| Calcium | 5 | 2017 | 480 | 0.370 |
Why?
|
| Mice, Knockout | 4 | 2024 | 933 | 0.370 |
Why?
|
| Mastocytoma | 1 | 2010 | 4 | 0.360 |
Why?
|
| Lymphocyte Activation | 8 | 2016 | 236 | 0.360 |
Why?
|
| Antigen Presentation | 1 | 2009 | 54 | 0.340 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 2 | 2008 | 9 | 0.340 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2010 | 55 | 0.320 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2008 | 30 | 0.310 |
Why?
|
| Mast-Cell Sarcoma | 1 | 2007 | 1 | 0.310 |
Why?
|
| Female | 17 | 2024 | 20969 | 0.310 |
Why?
|
| Gene Expression Regulation | 3 | 2019 | 1015 | 0.300 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2021 | 36 | 0.290 |
Why?
|
| Ascites | 3 | 2000 | 5 | 0.280 |
Why?
|
| Cell Cycle Proteins | 2 | 2021 | 229 | 0.280 |
Why?
|
| Disease Models, Animal | 4 | 2021 | 1371 | 0.270 |
Why?
|
| Homeostasis | 4 | 2022 | 188 | 0.270 |
Why?
|
| Immunologic Surveillance | 2 | 2019 | 5 | 0.270 |
Why?
|
| Chemokines | 2 | 2016 | 97 | 0.270 |
Why?
|
| Mice, Inbred C57BL | 3 | 2024 | 1609 | 0.240 |
Why?
|
| Memory Disorders | 1 | 2024 | 73 | 0.230 |
Why?
|
| Mitochondrial Proteins | 1 | 2024 | 107 | 0.230 |
Why?
|
| Flavoproteins | 2 | 2000 | 16 | 0.230 |
Why?
|
| Thymus Extracts | 1 | 2003 | 5 | 0.220 |
Why?
|
| Flow Cytometry | 3 | 2015 | 399 | 0.220 |
Why?
|
| Calcium-Binding Proteins | 3 | 2019 | 76 | 0.220 |
Why?
|
| Neoplasms, Experimental | 1 | 2003 | 37 | 0.220 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2015 | 98 | 0.220 |
Why?
|
| Male | 12 | 2024 | 20025 | 0.210 |
Why?
|
| Immunoblotting | 2 | 2015 | 176 | 0.210 |
Why?
|
| Adjuvants, Immunologic | 1 | 2003 | 107 | 0.210 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2022 | 63 | 0.200 |
Why?
|
| Astrocytes | 1 | 2024 | 255 | 0.200 |
Why?
|
| Melanoma, Experimental | 1 | 2021 | 9 | 0.200 |
Why?
|
| Poly I-C | 1 | 2021 | 7 | 0.200 |
Why?
|
| Withanolides | 1 | 2021 | 9 | 0.200 |
Why?
|
| Cell Survival | 3 | 2016 | 864 | 0.190 |
Why?
|
| Lymphocyte Count | 1 | 2021 | 46 | 0.190 |
Why?
|
| alpha-Defensins | 1 | 2021 | 17 | 0.190 |
Why?
|
| Enterotoxins | 1 | 2021 | 33 | 0.190 |
Why?
|
| Organoids | 1 | 2021 | 22 | 0.190 |
Why?
|
| Hippocampus | 1 | 2024 | 561 | 0.190 |
Why?
|
| Carcinoma, Large Cell | 1 | 2020 | 3 | 0.190 |
Why?
|
| Cell Differentiation | 3 | 2019 | 587 | 0.180 |
Why?
|
| Colitis, Ulcerative | 1 | 2021 | 54 | 0.180 |
Why?
|
| Crohn Disease | 1 | 2021 | 63 | 0.180 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2020 | 62 | 0.180 |
Why?
|
| Colon | 1 | 2021 | 103 | 0.180 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2022 | 149 | 0.180 |
Why?
|
| RNA Interference | 1 | 2021 | 243 | 0.180 |
Why?
|
| Biological Products | 1 | 2021 | 71 | 0.180 |
Why?
|
| Calcium Signaling | 3 | 2017 | 101 | 0.180 |
Why?
|
| Caspase 8 | 2 | 2010 | 32 | 0.170 |
Why?
|
| Models, Immunological | 1 | 2019 | 21 | 0.170 |
Why?
|
| Protease Inhibitors | 2 | 2008 | 49 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2017 | 269 | 0.150 |
Why?
|
| Leukemia | 2 | 2016 | 56 | 0.150 |
Why?
|
| Pore Forming Cytotoxic Proteins | 2 | 2015 | 5 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2015 | 1039 | 0.150 |
Why?
|
| Antigens, CD1 | 1 | 2017 | 5 | 0.150 |
Why?
|
| Aging, Premature | 1 | 2017 | 4 | 0.150 |
Why?
|
| Mice, Inbred DBA | 2 | 2010 | 71 | 0.150 |
Why?
|
| Organ Specificity | 2 | 2010 | 129 | 0.150 |
Why?
|
| Receptors, Cytokine | 1 | 2017 | 12 | 0.150 |
Why?
|
| Osteopontin | 1 | 2017 | 36 | 0.150 |
Why?
|
| Gene Expression Profiling | 2 | 2013 | 626 | 0.140 |
Why?
|
| Trialkyltin Compounds | 1 | 2016 | 2 | 0.140 |
Why?
|
| Cell Proliferation | 3 | 2021 | 1198 | 0.140 |
Why?
|
| STAT5 Transcription Factor | 1 | 2017 | 46 | 0.140 |
Why?
|
| Membrane Glycoproteins | 3 | 2020 | 211 | 0.140 |
Why?
|
| Brain | 1 | 2024 | 1346 | 0.140 |
Why?
|
| Immunohistochemistry | 2 | 2015 | 893 | 0.140 |
Why?
|
| Butyrates | 1 | 2016 | 31 | 0.140 |
Why?
|
| Nystatin | 1 | 2016 | 6 | 0.140 |
Why?
|
| Transcription Factors | 1 | 2021 | 681 | 0.140 |
Why?
|
| beta-Cyclodextrins | 1 | 2016 | 24 | 0.140 |
Why?
|
| Clinical Trials as Topic | 2 | 2015 | 204 | 0.140 |
Why?
|
| Neuronal Ceroid-Lipofuscinoses | 1 | 2015 | 4 | 0.140 |
Why?
|
| T-Box Domain Proteins | 1 | 2015 | 7 | 0.130 |
Why?
|
| Granzymes | 1 | 2015 | 16 | 0.130 |
Why?
|
| Energy Metabolism | 1 | 2017 | 168 | 0.130 |
Why?
|
| Membrane Microdomains | 1 | 2016 | 47 | 0.130 |
Why?
|
| Genes, ras | 1 | 2015 | 25 | 0.130 |
Why?
|
| Bystander Effect | 1 | 2015 | 11 | 0.130 |
Why?
|
| Genetic Engineering | 1 | 2015 | 33 | 0.130 |
Why?
|
| Inflammation Mediators | 1 | 2016 | 123 | 0.130 |
Why?
|
| Autoimmunity | 1 | 2015 | 53 | 0.130 |
Why?
|
| Immunologic Factors | 1 | 2015 | 45 | 0.130 |
Why?
|
| Ubiquitin | 1 | 2015 | 78 | 0.130 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2015 | 80 | 0.130 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2015 | 59 | 0.130 |
Why?
|
| Air Pollutants | 1 | 2016 | 94 | 0.120 |
Why?
|
| Benzo(a)pyrene | 1 | 2016 | 126 | 0.120 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2015 | 213 | 0.120 |
Why?
|
| Adoptive Transfer | 2 | 2015 | 48 | 0.120 |
Why?
|
| Melanoma | 1 | 2015 | 96 | 0.120 |
Why?
|
| NFATC Transcription Factors | 1 | 2014 | 6 | 0.120 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2007 | 356 | 0.120 |
Why?
|
| Environmental Pollutants | 1 | 2016 | 179 | 0.120 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2015 | 172 | 0.120 |
Why?
|
| Graft Rejection | 2 | 2019 | 38 | 0.120 |
Why?
|
| Mutation | 2 | 2015 | 1095 | 0.120 |
Why?
|
| Mice, SCID | 2 | 2015 | 150 | 0.120 |
Why?
|
| Aged | 2 | 2022 | 6741 | 0.110 |
Why?
|
| Gene Expression | 1 | 2016 | 674 | 0.110 |
Why?
|
| Ligands | 2 | 2020 | 349 | 0.110 |
Why?
|
| Caspase 3 | 2 | 2016 | 207 | 0.110 |
Why?
|
| Macrophages | 1 | 2016 | 439 | 0.100 |
Why?
|
| Cell Lineage | 2 | 2021 | 90 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2014 | 259 | 0.100 |
Why?
|
| DNA Fragmentation | 2 | 2003 | 92 | 0.100 |
Why?
|
| Receptor, Notch1 | 1 | 2011 | 17 | 0.100 |
Why?
|
| Cells, Cultured | 4 | 2021 | 1518 | 0.100 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2016 | 147 | 0.090 |
Why?
|
| Survival Rate | 2 | 2020 | 311 | 0.090 |
Why?
|
| Apoptosis Inducing Factor | 2 | 2000 | 7 | 0.090 |
Why?
|
| Death Domain Receptor Signaling Adaptor Proteins | 1 | 2010 | 3 | 0.090 |
Why?
|
| Interferon-gamma | 2 | 2003 | 250 | 0.090 |
Why?
|
| Lymphocyte Cooperation | 1 | 2010 | 6 | 0.090 |
Why?
|
| Clonal Deletion | 1 | 2010 | 3 | 0.090 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2010 | 4 | 0.090 |
Why?
|
| Immunologic Memory | 1 | 2010 | 38 | 0.090 |
Why?
|
| Cell Growth Processes | 1 | 2010 | 41 | 0.090 |
Why?
|
| Autoantigens | 1 | 2010 | 81 | 0.090 |
Why?
|
| Immunity, Cellular | 1 | 2010 | 70 | 0.090 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2010 | 64 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2008 | 152 | 0.080 |
Why?
|
| Mitochondrial Membranes | 1 | 2008 | 40 | 0.080 |
Why?
|
| Mice, Mutant Strains | 1 | 2007 | 80 | 0.080 |
Why?
|
| Immune System | 1 | 2007 | 41 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 306 | 0.070 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2006 | 56 | 0.070 |
Why?
|
| Receptors, Immunologic | 1 | 2006 | 61 | 0.070 |
Why?
|
| Autoimmune Diseases | 1 | 2006 | 57 | 0.070 |
Why?
|
| Radiation Chimera | 1 | 2004 | 7 | 0.060 |
Why?
|
| Bone Marrow Transplantation | 1 | 2004 | 15 | 0.060 |
Why?
|
| Stromal Cells | 1 | 2004 | 49 | 0.060 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2004 | 43 | 0.060 |
Why?
|
| Receptor, Adenosine A2B | 1 | 2023 | 4 | 0.060 |
Why?
|
| Atrophy | 1 | 2004 | 42 | 0.060 |
Why?
|
| Phosphates | 1 | 2023 | 51 | 0.060 |
Why?
|
| Reactive Oxygen Species | 2 | 2017 | 461 | 0.060 |
Why?
|
| Adenosine | 1 | 2023 | 59 | 0.060 |
Why?
|
| Stress, Physiological | 1 | 2004 | 150 | 0.050 |
Why?
|
| Organ Size | 1 | 2003 | 157 | 0.050 |
Why?
|
| Interferon Inducers | 1 | 2021 | 2 | 0.050 |
Why?
|
| Mucin-6 | 1 | 2021 | 7 | 0.050 |
Why?
|
| Ascitic Fluid | 1 | 2000 | 7 | 0.050 |
Why?
|
| Organ Culture Techniques | 1 | 2021 | 103 | 0.050 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2000 | 22 | 0.050 |
Why?
|
| Nucleosomes | 1 | 2000 | 29 | 0.050 |
Why?
|
| Culture Media | 1 | 2000 | 90 | 0.050 |
Why?
|
| Carboplatin | 1 | 2020 | 13 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 227 | 0.050 |
Why?
|
| Thymosin | 1 | 2000 | 2 | 0.050 |
Why?
|
| Antibodies | 1 | 2000 | 141 | 0.050 |
Why?
|
| Oligopeptides | 1 | 2000 | 102 | 0.050 |
Why?
|
| Biological Factors | 1 | 2000 | 6 | 0.050 |
Why?
|
| Mice, Nude | 1 | 2021 | 337 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 259 | 0.040 |
Why?
|
| Sodium Dodecyl Sulfate | 1 | 2000 | 21 | 0.040 |
Why?
|
| Th2 Cells | 1 | 2000 | 58 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2020 | 50 | 0.040 |
Why?
|
| Endocytosis | 1 | 2020 | 113 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 502 | 0.040 |
Why?
|
| Cell Division | 1 | 2000 | 307 | 0.040 |
Why?
|
| Th1 Cells | 1 | 2000 | 92 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2020 | 212 | 0.040 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2021 | 110 | 0.040 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2000 | 201 | 0.040 |
Why?
|
| 3T3 Cells | 1 | 2019 | 59 | 0.040 |
Why?
|
| Heart Transplantation | 1 | 2019 | 42 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2000 | 142 | 0.040 |
Why?
|
| Proteomics | 1 | 2021 | 325 | 0.040 |
Why?
|
| Logistic Models | 1 | 2021 | 923 | 0.040 |
Why?
|
| Prognosis | 1 | 2020 | 739 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2021 | 384 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 974 | 0.040 |
Why?
|
| Sperm Count | 1 | 2017 | 25 | 0.040 |
Why?
|
| Sperm Motility | 1 | 2017 | 38 | 0.040 |
Why?
|
| U937 Cells | 1 | 2016 | 27 | 0.040 |
Why?
|
| HL-60 Cells | 1 | 2016 | 32 | 0.030 |
Why?
|
| Sodium | 1 | 2016 | 103 | 0.030 |
Why?
|
| Valproic Acid | 1 | 2016 | 16 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2016 | 143 | 0.030 |
Why?
|
| Chemokine CCL5 | 1 | 2016 | 39 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 95 | 0.030 |
Why?
|
| Lung | 1 | 2019 | 446 | 0.030 |
Why?
|
| Receptors, IgG | 1 | 2016 | 50 | 0.030 |
Why?
|
| Endoplasmic Reticulum | 1 | 2016 | 105 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2015 | 45 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2016 | 136 | 0.030 |
Why?
|
| Adiposity | 1 | 2017 | 154 | 0.030 |
Why?
|
| Glycolysis | 1 | 2015 | 68 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2021 | 2026 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2016 | 234 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2016 | 237 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2015 | 295 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2015 | 196 | 0.030 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2013 | 5 | 0.030 |
Why?
|
| Antigens, CD1d | 1 | 2013 | 6 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2015 | 859 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 113 | 0.030 |
Why?
|
| Recurrence | 1 | 2013 | 131 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 2013 | 75 | 0.030 |
Why?
|
| Cell Movement | 1 | 2016 | 571 | 0.030 |
Why?
|
| Cell Line | 1 | 2016 | 1354 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 128 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2014 | 1180 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 1568 | 0.020 |
Why?
|
| Protein Binding | 1 | 2014 | 972 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2011 | 161 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 127 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2011 | 187 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2011 | 190 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2013 | 1369 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2010 | 444 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2010 | 222 | 0.020 |
Why?
|
| Perforin | 1 | 2008 | 10 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2008 | 116 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2010 | 513 | 0.020 |
Why?
|
| Receptors, Natural Killer Cell | 1 | 2006 | 1 | 0.020 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2006 | 23 | 0.020 |
Why?
|
| Middle Aged | 1 | 2020 | 10129 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2006 | 515 | 0.020 |
Why?
|
| Models, Biological | 1 | 2006 | 677 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2000 | 13 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 2000 | 46 | 0.010 |
Why?
|
| Gallic Acid | 1 | 2000 | 15 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2000 | 132 | 0.010 |
Why?
|